Design and initial evaluation of a certified committee model for review of in vivo gene therapy and related technologies, together with ex vivo gene therapy, under the act on the safety of regenerative medicine
Regenerative Therapy · 2026-12 · 33 · 101131
DOI: 10.1016/j.reth.2026.101131 ↗Kurz gefasst
Fachartikel in der Zeitschrift Regenerative Therapy, 2026-12. Verfasst von Hisako Katano und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Stem Cell and Regenerative Medicine, Department of Applied Regenerative Medicine, Institute of Science Tokyo (Science Tokyo), 1-5-45, Yush…. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Introduction
The 2024 amendment to the Act on the Safety of Regenerative Medicine expanded the Act's regulatory scope to include in vivo gene therapy and related technologies. This created a need for certified committees for regenerative medicine to address associated scientific and regulatory issues. This study aimed to design and provide an initial evaluation of a practical and implementable committee model for reviewing newly covered technologies and ex vivo gene therapy under the amended Act.
Methods
We conducted an institutional implementation study to develop a dual-committee model consisting of an independent second committee for gene therapy review, supported by selected shared foundational functions from an existing cell-based therapy committee. The success of the initial implementation was prospectively evaluated at the first review meeting using five predefined items: committee establishment, organizational structure, membership composition, workflow establishment, and operational feasibility.
Results
A newly established specific certified committee for regenerative medicine for gene therapy review was certified by the Ministry of Health, Labour and Welfare on November 28, 2025. The predefined organizational model was implemented as an independent second committee with a shared institutional foundation. The required membership categories were fulfilled, including those specific to gene therapy review. A standardized review workflow incorporating prior administrative checks and a preliminary document review was established and successfully applied at the first review meeting, without major procedural disruption.
Conclusions
A dual-committee model combining an independent second committee with a shared institutional foundation provided a practical and operationally feasible approach for implementing gene therapy review capacity within an existing regenerative medicine review infrastructure.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Stem Cell and Regenerative Medicine, Department of Applied Regenerative Medicine, Institute of Science Tokyo (Science Tokyo), 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
- Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
- Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Katano, H., Konomi, K., Nakamura, M., & Sekiya, I. (2026). Design and initial evaluation of a certified committee model for review of in vivo gene therapy and related technologies, together with ex vivo gene therapy, under the act on the safety of regenerative medicine. Regenerative Therapy, 33, 101131. https://doi.org/10.1016/j.reth.2026.101131
Vancouver
Katano H, Konomi K, Nakamura M, Sekiya I. Design and initial evaluation of a certified committee model for review of in vivo gene therapy and related technologies, together with ex vivo gene therapy, under the act on the safety of regenerative medicine. Regenerative Therapy. 2026;33:101131. doi:10.1016/j.reth.2026.101131
BibTeX
@article{Katano2026,
author = {Katano, Hisako and Konomi, Kenji and Nakamura, Masaya and Sekiya, Ichiro},
title = {Design and initial evaluation of a certified committee model for review of in vivo gene therapy and related technologies, together with ex vivo gene therapy, under the act on the safety of regenerative medicine},
journal = {Regenerative Therapy},
year = {2026},
volume = {33},
pages = {101131},
doi = {10.1016/j.reth.2026.101131}
}
EUVIMED